CagriSema Phase 3 Trial Shows Superior HbA1c Reduction and Weight Loss in Type 2 Diabetes
NVO sits 37% above its 52-week low of $43.08.
Summary
Novo Nordisk's CagriSema achieved superior HbA1c reduction and weight loss in a Phase 3 trial for type 2 diabetes, outperforming semaglutide and strengthening the company's pipeline.
Key Events · Product Development and Regulatory · NVO
-
Superior Efficacy in Phase 3 Trial
CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial, compared to semaglutide.
-
Strong Weight Loss Profile
Up to 43% of participants achieved ≥15% weight loss, and up to 24% achieved ≥20% weight loss, with no weight loss plateau observed at week 68.
-
Favorable Safety Profile
CagriSema appeared safe and well-tolerated, with gastrointestinal adverse events being the most common, consistent with incretin and amylin-based therapies.
-
Regulatory Pathway Discussions Planned
Following these results, Novo Nordisk will engage with authorities to discuss the regulatory pathway for CagriSema in type 2 diabetes, building on the recent FDA submission for weight management.
Analysis · NVO · Life Sciences
Novo Nordisk announced highly positive headline results from its REIMAGINE 2 Phase 3 trial for CagriSema, a fixed-dose combination of cagrilintide and semaglutide, in adults with type 2 diabetes. The trial demonstrated superior reductions in both HbA1c (1.91%-points) and body weight (14.2%) compared to semaglutide alone. These results are significant as they indicate CagriSema could offer a more effective treatment option than current market leaders, including Novo Nordisk's own semaglutide-based products. The company plans to discuss the regulatory pathway with authorities, potentially expanding its dominant position in the diabetes and obesity markets.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.5% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVO was trading at $59.13 on NYSE in the Life Sciences sector, with a market capitalization of approximately $259.7B. The 52-week trading range was $43.08 to $93.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.